The Oral Selective Inhibitor of Nuclear Export ( SINE) Selinexor (KPT-330) Demonstrates Broad and Durable Clinical Activity in Relapsed / Refractory Non Hodgkin's Lymphoma (NHL)

被引：0

作者：

Kuruvilla, John ^{[1
]}

Byrd, John C. ^{[2
]}

Flynn, Joseph M. ^{[3
]}

Garzon, Ramiro ^{[3
]}

Porcu, Pierluigi ^{[2
]}

Wagner-Johnston, Nina ^{[4
]}

Savoie, Mary Lynn ^{[5
]}

Stone, Richard M. ^{[6
]}

Jacobsen, Eric D. ^{[6
]}

Mau-Sorensen, Morten ^{[7
]}

Brown, Peter de Nully ^{[8
]}

Baz, Rachid ^{[9
]}

Shal, Bijal ^{[9
]}

Flinn, Ian ^{[10
]}

Gabrail, Nashat ^{[11
]}

Kukreti, Vishal ^{[12
]}

Tiedemann, Rodger E. ^{[12
]}

Landesman, Yosef ^{[13
]}

Klebanov, Boris ^{[13
]}

Shacham, Eran ^{[13
]}

Saint-Martin, Jean-Richard ^{[13
]}

Marshall, Tracey ^{[13
]}

McCartney, John ^{[13
]}

McCauley, Dilara ^{[13
]}

Carlson, Robert ^{[13
]}

Norori, Sasha ^{[14
]}

Savona, Michael R. ^{[13
]}

Rashal, Tami ^{[13
]}

Mirza, Mansoor R. ^{[13
]}

Kauffman, Michael ^{[13
]}

Shacham, Sharon ^{[13
]}

机构：

[1] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada

[2] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA

[3] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA

[4] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA

[5] Alberta Hlth Serv, Calgary, AB, Canada

[6] Dana Farber Canc Inst, Boston, MA 02115 USA

[7] Rigshosp, Dept Oncol, DK-2100 Copenhagen, Denmark

[8] Rigshosp, DK-2100 Copenhagen, Denmark

[9] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA

[10] Sarah Cannon Res Inst, Nashville, TN USA

[11] Gabrail Canc Ctr, Canton, OH USA

[12] Princess Margaret Canc Ctr, Toronto, ON, Canada

[13] Karyopharm Therapeut Inc, Newton, MA USA

[14] Ozmosis Res Inc, Toronto, ON, Canada

来源：

BLOOD | 2014年 / 124卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[21] Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer
Kazim, Sabiha
Malafa, Mokenge P.
Coppola, Domenico
Husain, Kazim
Zibadi, Sherma
Kashyap, Trinayan
Crochiere, Marsha
Landesman, Yosef
Rashal, Tami
Sullivan, Daniel M.
Mahipal, Amit
MOLECULAR CANCER THERAPEUTICS, 2015, 14 (07) : 1570 - 1581
[22] Selinexor (KPT-330), an oral Selective Inhibitor of Nuclear Export (SINE) compound, in combination with FOLFOX in patients with metastatic colorectal cancer (mCRC) - final results of the phase I SENTINEL trial
Nilsson, S.
Stein, A.
Rolfo, C.
Kranich, A.
Quidde, J.
Papadimitriou, K.
Theile, S.
Amberg, S.
Bokemeyer, C.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 122 - 122
[23] Selinexor (KPT-330), an Oral Selective Inhibitor of Nuclear Export (SINE) Compound, in Combination with FOLFOX in Patients with Metastatic Colorectal Cancer (mCRC) - Final Results of the Phase I Trial SENTINEL
Nilsson, Sven
Stein, Alexander
Rolfo, Christian
Kranich, Anne L.
Mann, Julia
Papadimitriou, Konstantinos
Theile, Susann
Amberg, Stefanie
Bokemeyer, Carsten
CURRENT CANCER DRUG TARGETS, 2020, 20 (10) : 811 - 817
[24] Nuclear export inhibitor selinexor (KPT-330) demonstrates anti-tumor efficacy alone and in combination with chemotherapy in multiple breast cancer models
Arango, Natalia Paez
Evans, Kurt
Zhao, Ming
Yuca, Erkan
Scott, Stephen
Kim, Charissa
Naing, Aung
Meric-Bernstam, Funda
CANCER RESEARCH, 2016, 76
[25] A phase 1b food effect study of the first-in-class, oral, selective inhibitor of nuclear export (SINE) selinexor (KPT-330) in patients (pts) with advanced sarcomas.
Gounder, Mrinal M.
Loong, Herbert H. F.
Nyquist-Schultz, Kjirsten
Baker, Stephanie
Ustoyev, Yelena
Tanner, Lanier R.
Shacham, Sharon
McCauley, Dilara
Rashal, Tami
Saint-Martin, Jean-Richard
Shacham, Eran
Friedlander, Sharon
Tamir, Sharon
Marshall, Tracey
Landesman, Yosef
Kauffman, Michael
Rebello, Sasha
Mirza, Mansoor Slide Raza
Schwartz, Gary K.
Razak, Albiruni R. A.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[26] THE COMBINATION OF SELINEXOR (KPT-330), A SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE), & THE FLT3 INHIBITOR QUIZATINIB SHOWS ANTI-TUMOR ACTIVITY IN ACUTE MYELOID LEUKEMIA (AML) IN VITRO AND IN VIVO
Carlson, R.
Senapedis, W.
Landesman, Y.
Shacham, S.
HAEMATOLOGICA, 2014, 99 : 290 - 291
[27] Selective Inhibitor of Nuclear Export Selinexor (KPT-330) and BCL2 Inhibitor ABT-199 Enhance the Anti-Lymphoma Effect of BTK Inhibitor Ibrutinib in Mantle Cell Lymphoma
Tabe, Yoko
Harada, Masako
Miyamae, Yuka
Kazuno, Saiko
Fujimura, Tsutomu
Ueno, Takashi
Miida, Takashi
Konopleva, Marina
Andreeff, Michael
BLOOD, 2014, 124 (21)
[28] TOPICAL SELINEXOR (KPT-330), A SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) SHOWS INCREASED BLOOD FLOW AND ACCELERATED HEALING USING NONINVASIVE TECHNIQUES IN AN ISCHEMIC MODEL OF WOUND HEALING
Ganesh, K.
Kitsos, C.
Rashal, T.
Roy, S.
Gnyawali, S.
Friedlander, S.
Chen, W.
Ellis, J.
Austad, B.
McCauley, D.
Kauffman, M.
Shacham, S.
Sen, C.
WOUND REPAIR AND REGENERATION, 2015, 23 (02) : A22 - A22
[29] KCP-330-005/SIGN: A PHASE II, OPEN-LABEL STUDY OF EFFICACY AND SAFETY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) KPT-330 (SELINEXOR) IN PATIENTS WITH ADVANCED GYNAECOLOGIC MALIGNANCIES
Vergote, I.
Lund, B.
Ujmajuridze, Z.
Havsteen, H.
Rashal, T.
Marshall, T.
McCartney, J.
Kauffman, M.
Shacham, S.
Mirza, M. R.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 1182 - 1183
[30] Preclinical activity in non-Hodgkin's lymphoma of Selinexor, a selective inhibitor of nuclear export (SINE), is enhanced through combination with standard-of-care therapies
Azmi, Asfar S.
Aboukameel, Amro
Carlson, Robert O.
Elloul, Sivan
Shacham, Sharon
Kauffman, Michael
Frenkel, Ran
Mohammad, Ramzi M.
CANCER RESEARCH, 2015, 75

← 1 2 3 4 5 →